Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-02
1999-07-06
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514412, 514416, 514417, 514418, 514424, 514425, 546 18, 546122, 546139, 546249, 548472, 548475, 548486, 548512, 548514, 548530, 5483001, 548146, 560312, 562444, 544242, 549 29, 549 49, 549434, A61K 31405, A61K 3144, C07C25908, C07C22932, C07D20934, C07D20946, C07D20948, C07D22120
Patent
active
059197900
ABSTRACT:
The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
REFERENCES:
patent: 5656627 (1997-08-01), Bemis et al.
Allen Hamish John
Brady Kenneth Dale
Caprathe Bradley William
Galatsis Paul
Gilmore John Lodge
BASF Aktiengesellsschaft
Crissey Todd M.
Oswecki Jane C.
Richter Johann
Warner-Lambert & Company
LandOfFree
Hydroxamate inhibitors of interleukin-1.beta. converting enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxamate inhibitors of interleukin-1.beta. converting enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamate inhibitors of interleukin-1.beta. converting enzyme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-899231